Lexeo Therapeutics (LXEO) Total Liabilities (2022 - 2026)

Lexeo Therapeutics has reported Total Liabilities for 5 years, with the latest figure at $18.9 million in Q1 2026.

• Quarterly Total Liabilities fell 49.81% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (down 49.81% YoY) and the FY2025 annual result came in at $22.0 million, down 26.85% from the prior year.
• Total Liabilities slipped to $18.9 million in Q1 2026 per LXEO's latest filing, from $22.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $37.8 million in Q2 2025 and troughed at $18.9 million in Q1 2026.
• A 5-year average of $28.8 million and a median of $28.6 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities jumped 39.88% in 2025, then slumped 49.81% in 2026.
• Over 5 years, Total Liabilities stood at $25.0 million in 2022, then grew by 5.1% to $26.3 million in 2023, then rose by 14.57% to $30.1 million in 2024, then fell by 26.85% to $22.0 million in 2025, then slipped by 14.35% to $18.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $18.9 million, $22.0 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.